A Phase II/III Study of N-803 (ALT-803) Plus Pembrolizumab Versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)

Protocol No
SWOG-S1800D-ALT-803
Principal Investigator
Smitha Menon
Phase
II/III
Summary
This study is being done to answer the following question: Can we extend your life by combining two drugs that work with the immune system to fight cancer? We are doing this study because we want to find out if this approach is better or worse than the usual approach for lung cancer. The usual approach is defined as care most people get for lung cancer.
Description
Testing the Use of Combination Immunotherapy
Treatment (N-803 (ALT-803) plus Pembrolizumab) against the Usual Treatment
for Advanced Non-Small Cell Lung Cancer
Participating Institutions
Froedtert Hospital
Froedtert Menomonee Falls Hospital
Froedtert West Bend Hospital
Status
OPEN TO ACCRUAL
Sub Category